← Back to Search

Intracranial Monitoring Tasks for Language Disorders

N/A

Recruiting

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between ages 18 - 85

Be older than 18 years old

Must not have

Inability to understand or perform the task outlined in the protocol, or who are unwilling or unable to participate

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout intracranial monitoring period, up to approximately 10 days

Awards & highlights

No Placebo-Only Group

Summary

This trial will help researchers understand how the brain processes speech, which could lead to new treatments for speech disorders.

Who is the study for?

This trial is for adults aged 18-85 with language disorders or epilepsy who are already scheduled for intracranial monitoring of the left cerebral hemisphere. Participants must be able to follow test instructions and give informed consent.

What is being tested?

The study investigates how the human brain processes language by having participants perform behavioral tasks during intracranial monitoring, aiming to combine neural data with computational models of cognition.

What are the potential side effects?

Since this trial involves non-invasive behavioral tasks during a procedure that patients are already undergoing, there are no additional side effects directly associated with the study itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I understand and can follow the study's requirements.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout intracranial monitoring period, up to approximately 10 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout intracranial monitoring period, up to approximately 10 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout intracranial monitoring period, up to approximately 10 days for reporting.